Sinopharm Accord(SZ:000028) Xin Lang Cai Jing·2025-10-31 01:56Core Insights - The company reported a total revenue of 55.124 billion yuan for Q3 2025, ranking 4th among peers, with a year-on-year decrease of 2.38% [1] - The net profit attributable to shareholders was 0.957 billion yuan, ranking 6th among peers, reflecting a year-on-year decline of 10.18% [1] - The net cash flow from operating activities was -0.463 billion yuan, ranking 27th among peers, showing a significant year-on-year decrease of 136.15% [1] Financial Performance - The latest debt-to-asset ratio is 57.39%, ranking 13th among peers, with a decrease of 0.47 percentage points from the previous quarter and 0.96 percentage points from the same period last year [3] - The latest gross profit margin is 10.49%, ranking 20th among peers, down by 0.20 percentage points from the previous quarter and 0.39 percentage points year-on-year [3] - The latest return on equity (ROE) is 5.19%, ranking 14th among peers, with a decrease of 0.69 percentage points from the same period last year [3] Earnings and Ratios - The diluted earnings per share (EPS) is 1.72 yuan, ranking 2nd among peers, representing a year-on-year decrease of 9.95% [3] - The total asset turnover ratio is 1.12 times, ranking 6th among peers, with a slight decrease of 0.01 times year-on-year [3] - The inventory turnover ratio is 6.27 times, ranking 5th among peers, showing an increase of 1.99% year-on-year, marking three consecutive years of growth [3] Shareholder Structure - The number of shareholders is 41,400, with the top ten shareholders holding 345 million shares, accounting for 62.05% of the total share capital [3] - The largest shareholder is China National Pharmaceutical Group Co., Ltd., holding 56.06% of the shares [3]